Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
NMRA Stock Chart & Stats
$3.49
-$0.22(-8.53%)
At close: 4:00 PM EST
$3.49
-$0.22(-8.53%)
Day’s Range― - ―
52-Week Range$0.61 - $3.65
Previous CloseN/A
Volume2.95M
Average Volume (3M)490.26K
Market Cap
$583.14M
Enterprise Value$454.59M
Total Cash (Recent Filing)$171.53M
Total Debt (Recent Filing)$523.00K
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Mar 11, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding167,089,110
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio-2.58
Price to Book (P/B)5.89
Price to Sales (P/S)0.00
P/FCF Ratio-9.23
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-90.92
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$10.17Price Target Upside191.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$625.00K
Bulls Say, Bears Say
Bulls Say
Favorable Safety And Dosing PotentialNMRA-511 showed mostly mild to moderate adverse events and lacks a competitor's boxed warning, supporting potential for higher dosing and a safer, non‑sedative positioning for elderly patients.
Pipeline Optionality And Strategic DevelopmentA diversified pipeline that includes an inflammation-targeting obesity asset and a KOR antagonist program, together with plans for higher-dose cohorts and an extended‑release formulation, creates multiple paths for positive clinical or commercial catalysts.
Targeted Clinical EfficacyNMRA-511 produced a consistent treatment signal in patients with elevated baseline anxiety, indicating that enrollment strategies focused on this subgroup could reveal a clear benefit and improve chances of success in later trials.
Bears Say
Limited Broad Efficacy EvidenceSeparation from placebo was most notable only within a subgroup with pronounced anxiety, which could make it challenging to demonstrate broad effectiveness in a general agitation population without targeted enrichment.
Regulatory And Clinical Development RiskNo approved products and reliance on small, signal-finding studies that were not powered for definitive efficacy create significant regulatory and execution risk for achieving commercial viability.
Safety Signal From Sodium AbnormalitiesInstances of low sodium and a serious hyponatremia event that led to treatment discontinuation highlight a safety concern that will need to be resolved to satisfy regulators and clinicians.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.61 and its highest was $3.65 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $583.14M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2026 which is in 10 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.333 by -$0.017.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 167,089,110 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.333. Following the earnings report the stock price went down -1.527%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.17 (191.40% Upside)
$10.17 (191.40% Upside)
Hedge Fund Trend
Increased
By 179.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $77.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
-104.35%
Trailing 12-Months
Asset Growth
-44.66%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
NMRA Stock 12 Month Forecast
Average Price Target
$10.17
▲(191.40% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
65.90% Insiders
3.78% Mutual Funds
10.79% Other Institutional Investors
16.35% Public Companies and
Individual Investors